Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.

Journal of clinical microbiology - 23 Dec 2019

Oštrbenk Valenčak Anja, Šterbenc Anja, Seme Katja, Poljak Mario

Abstract excerpt

The Alinity m HR HPV assay (Alinity) is a novel human papillomavirus (HPV) assay that individually identifies genotypes HPV16, HPV18, and HPV45 while reporting on 11 other high-risk HPV (hrHPV) genotypes in two aggregates: HPV31/33/52/58 and HPV35/39/51/56/59/66/68. The clinical performance of Alinity for screening for cervical cancer was evaluated in population-based settings. For women aged ≥30 years, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colposcopy
Share to Cytological Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Early Detection of Cancer

Share to Mass Screening

Share to Molecular Typing

Share to Papillomaviridae

Share to Uterine Cervical Dysplasia

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31666369
DOI: 10.1128/JCM.01120-19
PMCID: PMC6935899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.PMID 31666369Read ↗

Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.Semantic proximity Read ↗

Clinical Performance of the Alinity m HR HPV Assay in a Large Urban Cervical Cancer Screening Program in the United StatesSemantic proximity Read ↗

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results.Semantic proximity Read ↗

HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China.Semantic proximity Read ↗

High-Risk Human Papillomavirus Detection via Cobas® 4800 and REBA HPV-ID® Assays.Semantic proximity Read ↗

Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High-Risk Human Papillomavirus Genotyping in Cervical Samples.Semantic proximity Read ↗

Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study.Semantic proximity Read ↗

Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.Semantic proximity Read ↗

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.Semantic proximity Read ↗

Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.Semantic proximity Read ↗

Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.